Protagen Applying UNIarray Platform for Biogen's MS Drug Research
March 29, 2011
Protagen Applying UNIarray Platform for Biogen's MS Drug Research
Under the terms of an agreement, Protagen's UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work
April 1, 2011 / ProteoMonitor - Protagen to Use UniArray Platform to Discover Multiple Sclerosis Biomarkers for Biogen Idec
March 29, 2011 / BioArray News - Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation
September 10, 2010 / ProteoMonitor - Protagen Hopes to Have Diagnostics Deal Inked by End of 2010, Says CEO
June 30, 2009 / BioArray News - Myriad, DaVita Team on Protein Marker Research
June 17, 2013 / GenomeWeb Daily News